Lutein and zeaxanthin supplementation and association with visual function in age-related macular degeneration

Investigative Ophthalmology and Visual Science

Volumn 56, Issue 1, 2015, Pages 252-258

  Liu, Rong ^a   Wang, Tian ^a   Zhang, Bao ^a   Qin, L ^b   Wu, Changrui ^b   Li, Qingshan ^a   Ma, L ^a  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Age related macular degeneration; Lutein; Meta analysis; Visual function; Zeaxanthin

Indexed keywords

ANTIOXIDANT; PLACEBO; XANTHOPHYLL; ZEAXANTHIN;

AGE RELATED MACULAR DEGENERATION; ARTICLE; CONTRAST SENSITIVITY; CONTROLLED STUDY; DISEASE ASSOCIATION; GLARE RECOVERY TIME; HUMAN; MACULAR PIGMENT OPTICAL DENSITY; META ANALYSIS; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUBJECTIVE PERCEPTION; VISION; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS; DIET SUPPLEMENTATION; DRUG EFFECTS; MACULAR DEGENERATION; PATHOPHYSIOLOGY; PHYSIOLOGY;

DIETARY SUPPLEMENTS; HUMANS; LUTEIN; MACULAR DEGENERATION; VISUAL ACUITY; ZEAXANTHINS;

EID: 84920923138     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.14-15553     Document Type: Article

References (44)

1. Chew EY, Clemons TE, Agrón E, et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmol. 2014;132: 272–277.
2. Miller JW. Age-related macular degeneration revisited-piecing the puzzle: the LXIX Edward Jackson memorial lecture. Am J Ophthalmol. 2013;155:1–35.
3. Rein DB, Wittenborn JS, Zhang X, et al. Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments. Arch Ophthalmol. 2009;127:533–540.
4. Cheung CM, Wong TY. Treatment of age-related macular degeneration. Lancet. 2013;382:1230–1232.
5. Han DP. Age-related macular degeneration, anti-VEGF therapy, and ophthalmic imaging: is there a best practice? JAMA Ophthalmol. 2013;131:1124–1126.
6. Hollyfield JG. Age-related macular degeneration: the molecular link between oxidative damage, tissue-specific inflammation and outer retinal disease: the Proctor lecture. Invest Ophthalmol Vis Sci. 2010;51:1275–1281.
7. Loane E, Kelliher C, Beatty S, Nolan JM. The rationale and evidence base for a protective role of macular pigment in agerelated maculopathy. Br J Ophthalmol. 2008;92:1163–1168.
8. Arnold C, Winter L, Fröhlich K, et al. Macular xanthophylls and x-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial. JAMA Ophthalmol. 2013;131:564–572.
9. Barker FM, Snodderly DM, Johnson EJ, et al. Nutritional manipulation of primate retinas, V: effects of lutein, zeaxanthin, and n-3 fatty acids on retinal sensitivity to blue-lightinduced damage. Invest Ophthalmol Vis Sci. 2011;52:3934–3942.
10. Berrow EJ, Bartlett HE, Eperjesi F, Gibson JM. The effects of a lutein-based supplement on objective and subjective measures of retinal and visual function in eyes with age-related maculopathy-a randomised controlled trial. Br J Nutr. 2013; 109:2008–2014.
11. Ho L, van Leeuwen R, Witteman JC, et al. Reducing the genetic risk of age-related macular degeneration with dietary antioxidants, zinc, and x-3 fatty acids: the Rotterdam study. Arch Ophthalmol. 2011;129:758–766.
12. Age-Related Eye Disease Study Research Group. The relationship of dietary carotenoid and vitamin A, E, and C intake with age-related macular degeneration in a case-control study: AREDS Report No. 22. Arch Ophthalmol. 2007;125:1225–1232.
13. Piermarocchi S, Saviano S, Parisi V, et al. Carotenoids in Agerelated Maculopathy Italian Study (CARMIS): two-year results of a randomized study. Eur J Ophthalmol. 2012;22:216–225.
14. Richer SP, Stiles W, Statkute L, et al. Double-masked, placebocontrolled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). Optometry. 2004;75:216–230.
15. Rosenthal JM, Kim J, de Monasterio F, et al. Dose-ranging study of lutein supplementation in persons aged 60 years or older. Invest Ophthalmol Vis Sci. 2006;47:5227–5233.
16. Puell MC, Palomo-Alvarez C, Barrio AR, Gómez-Sanz FJ, Pérez- Carrasco MJ. Relationship between macular pigment and visual acuity in eyes with early age-related macular degeneration. Acta Ophthalmol. 2013;91:e298–e303.
17. Richer SP, Stiles W, Graham-Hoffman K, et al. Randomized, double-blind, placebo-controlled study of zeaxanthin and visual function in patients with atrophic age-related macular degeneration: the Zeaxanthin and Visual Function Study (ZVF) FDA IND #78, 973. Optometry. 2011;82:667–680.
18. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
19. Kaiser PK. Prospective evaluation of visual acuity assessment: a comparison of Snellen versus ETDRS charts in clinical practice (An AOS Thesis). Trans Am Ophthalmol Soc. 2009; 107:311–324.
20. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12.
21. Egger M, Davey Smith G, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. BMJ. 1997;315: 629–634.
22. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50: 1088–1101.
23. Bartlett HE, Eperjesi F. Effect of lutein and antioxidant dietary supplementation on contrast sensitivity in age-related macular disease: a randomized controlled trial. Eur J Clin Nutr. 2007; 61:1121–1127.
24. Ma L, Yan SF, Huang YM, et al. Effect of lutein and zeaxanthin on macular pigment and visual function in patients with early age-related macular degeneration. Ophthalmology. 2012;119: 2290–2297.
25. Weigert G, Kaya S, Pemp B, et al. Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. Invest Ophthalmol Vis Sci. 2011;52:8174–8178.
26. Dawczynski J, Jentsch S, Schweitzer D, Hammer M, Lang GE, Strobel J. Long term effects of lutein, zeaxanthin and omega-3- LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study. Graefes Arch Clin Exp Ophthalmol. 2013;251:2711–2723.
27. Murray IJ, Makridaki M, van der Veen RL, Carden D, Parry NR, Berendschot TT. Lutein supplementation over a one-year period in early AMD might have a mild beneficial effect on visual acuity: the CLEAR study. Invest Ophthalmol Vis Sci. 2013;54:1781–1788.
28. Beatty S, Chakravarthy U, Nolan JM, et al. Secondary outcomes in a clinical trial of carotenoids with coantioxidants versus placebo in early age-related macular degeneration. Ophthalmology. 2013;120:600–606.
29. Kumar N, Mrejen S, Fung AT, Marsiglia M, Loh BK, Spaide RF. Retinal pigment epithelial cell loss assessed by fundus autofluorescence imaging in neovascular age-related macular degeneration. Ophthalmology. 2013;120:334–341.
30. Kinnunen K, Petrovski G, Moe MC, Berta A, Kaarniranta K. Molecular mechanisms of retinal pigment epithelium damage and development of age-related macular degeneration. Acta Ophthalmol. 2012;90:299–309.
31. Zeng S, Hernández J, Mullins RF. Effects of antioxidant components of AREDS vitamins and zinc ions on endothelial cell activation: implications for macular degeneration. Invest Ophthalmol Vis Sci. 2012;53:1041–1047.
32. Lien EL, Hammond BR. Nutritional influences on visual development and function. Prog Retin Eye Res. 2011;30: 188–203.
33. Chen X, Li Q, Liu X, Yang L, Xia W, Tao L. Visual acuity evaluated by pattern-reversal visual-evoked potential is affected by check size/visual angle. Neurosci Bull. 2012;28:737–745.
34. Bühren J, Terzi E, Bach M, Wesemann W, Kohnen T. Measuring contrast sensitivity under different lighting conditions: comparison of three tests. Optom Vis Sci. 2006;83:290–298.
35. Yu CC, Nandrot EF, Dun Y, Finnemann SC. Dietary antioxidants prevent age-related retinal pigment epithelium actin damage and blindness in mice lacking avb5 integrin. Free Radic Biol Med. 2012;52:660–670.
36. Kim SR, Nakanishi K, Itagaki Y, Sparrow JR. Photooxidation of A2-PE, a photoreceptor outer segment fluorophore, and protection by lutein and zeaxanthin. Exp Eye Res. 2006;82: 828–839.
37. Bian Q, Gao S, Zhou J, et al. Lutein and zeaxanthin supplementation reduces photooxidative damage and modulates the expression of inflammation-related genes in retinal pigment epithelial cells. Free Radic Biol Med. 2012;53:1298–1307.
38. Thomson LR, Toyoda Y, Delori FC, et al. Long term dietary supplementation with zeaxanthin reduces photoreceptor death in light-damaged Japanese quail. Exp Eye Res. 2002;75: 529–542.
39. Kijlstra A, Tian Y, Kelly ER, Berendschot TT. Lutein: more than just a filter for blue light. Prog Retin Eye Res. 2012;31:303–315.
40. Siedlecki D, Jóźwik A, Zając M, Hill-Bator A, Turno-Kręcicka A. In vivo longitudinal chromatic aberration of pseudophakic eyes. Optom Vis Sci. 2014;91:240–246.
41. Hammond BR Jr, Fletcher LM. Influence of the dietary carotenoids lutein and zeaxanthin on visual performance: application to baseball. Am J Clin Nutr. 2012;96:1207S–1213S.
42. Bibiloni Mdel M, Zapata ME, Aragón JA, Pons A, Olea JL, Tur JA. Estimation of antioxidants dietary intake in wet age-related macular degeneration patients. Nutr Hosp. 2014;29:880–888.
43. Cangemi FE. TOZAL Study: an open case control study of an oral antioxidant and omega-3 supplement for dry AMD. BMC Ophthalmol. 2007;7:3.
44. Horn SD, DeJong G, Deutscher D. Practice-based evidence research in rehabilitation: an alternative to randomized controlled trials and traditional observational studies. Arch Phys Med Rehabil. 2012;93:S127–S137.